Debiopharm

Debiopharm is a global biopharmaceutical company focused on developing innovative therapies to address high unmet medical needs, primarily in oncology and bacterial infections. They develop high-potential compounds and technologies, clinically demonstrate their safety and efficacy, and then partner with larger pharmaceutical companies for global commercialization. Currently, they are developing Debio 1453, a novel antibiotic to combat drug-resistant Neisseria gonorrhoeae infections.

Funding Round: Preclinical Development

Funding Amount: $5.76M

Date: 21-Nov-2024

Investors: CARB-X

Markets: Pharmaceuticals, Antibacterial, Infectious Diseases

HQ: Lausanne, Vaud, Switzerland

Founded: 1979

Website: https://www.debiopharm.com/

LinkedIn: https://www.linkedin.com/company/debiopharminternational/

Twitter: http://twitter.com/DebiopharmNews

Instagram:

Facebook: http://www.facebook.com/pages/Debiopharm-Group